drugset / Trial / NCT02706184

E. Coli Nissle in Oncology

NCT02706184 ↗

Phase 3 Completed 20 enrolled University of Hohenheim Ardeypharm GmbH · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

In patients with gastric or colorectal cancers, where a treatment with 5-Fluoruracil in combination with other chemotherapeutic remedies (FLO, FOLFOX, FOLFOX-Bev, FOLFIRI) is planned, it shall be investigated whether E. coli Nissle suspension has an effect on duration and intensity of chemotherapy induced diarrhea.

Timeline

Start
2015-07
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject E. coli Nissle suspension Unknown — —